Stemline Therapeutics (STML) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stemline Therapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 4:00 PM EDTNEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel oncology drugs that primarily target cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended June 30, 2015.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "This quarter, we began enrollment in the expansion stage of our SL-401 pivotal trial in BPDCN, a highly aggressive malignancy of unmet medical need. This follows completion of the lead-in stage of this trial, wherein we evaluated multiple cycle SL-401 administration at escalating doses in... More
Stemline Therapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 4:00 PM EDTNEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel oncology drugs that primarily target cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended June 30, 2015.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "This quarter, we began enrollment in the expansion stage of our SL-401 pivotal trial in BPDCN, a highly aggressive malignancy of unmet medical need. This follows completion of the lead-in stage of this trial, wherein we evaluated multiple cycle SL-401 administration at escalating doses in... More
Stemline Therapeutics to Present at the 2015 Wedbush PacGrow Healthcare Conference
August 6, 2015 8:00 AM EDTNEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2015 at 2:30 PM ET. The conference will be held at the Le Parker Meridien Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
About Stemline Therapeutics
Stemline... More
